P
Peter E. Penson
Researcher at Liverpool John Moores University
Publications - 119
Citations - 2184
Peter E. Penson is an academic researcher from Liverpool John Moores University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 21, co-authored 94 publications receiving 1139 citations. Previous affiliations of Peter E. Penson include University of Liverpool & Cardiff University.
Papers
More filters
Journal ArticleDOI
The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
Bożena Sosnowska,Mohsen Mazidi,Peter E. Penson,Anna Gluba-Brzózka,Jacek Rysz,Maciej Banach,Maciej Banach,Maciej Banach +7 more
TL;DR: Encouraging observations from preclinical studies necessitate rigorous large, prospective, randomized clinical trials to determine the roles of SIRT activators on the progression of atherosclerosis and ultimately on cardiac outcomes, such as myocardial infarction and mortality.
Journal ArticleDOI
Prevalence of statin intolerance: a meta-analysis
Ibadete Bytyçi,Peter E. Penson,Dimitri P. Mikhailidis,Nathan D. Wong,Adrian V. Hernandez,Amirhossein Sahebkar,Paul M. Thompson,Mohsen Mazidi,Jacek Rysz,Daniel Pella,Zeljko Reiner,Peter P. Toth,Maciej Banach +12 more
TL;DR: The results support the concept that the prevalence of complete SI might often be overestimated and highlight the need for the careful assessment of patients with potential symptoms related to SI.
Journal ArticleDOI
The Role of Nutraceuticals In The Prevention of Cardiovascular Disease
TL;DR: The aim of this review is to present an update on the most recent evidence relating to the use of nutraceuticals in the context of the prevention and treatment of CVD.
Journal ArticleDOI
Inclisiran-New hope in the management of lipid disorders?
Krzysztof Dyrbuś,Mariusz Gąsior,Peter E. Penson,Kausik K. Ray,Maciej Banach,Maciej Banach,Maciej Banach +6 more
TL;DR: Inclisiran represents an entirely new mechanism of PSCK9 protein inhibition in hepatocytes, targeting the messenger RNA for PCSK9, and its administration is necessary only every 3 to 6 months, which is an essential advantage over statin and monoclonal antibody therapy.
Journal ArticleDOI
Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
Peter E. Penson,G.B. John Mancini,Peter P. Toth,Seth S. Martin,Gerald F. Watts,Amirhossein Sahebkar,Dimitri P. Mikhailidis,Maciej Banach,Maciej Banach,Maciej Banach +9 more
TL;DR: The concept of ‘drucebo’ is introduced to relate to beneficial or adverse effects of a drug, which result from expectation and are not pharmacologically caused by the drug.